Chasing Pfizer and Roche, Regenxbio benefits from FDA boost for DMD gene therapy

Chasing Pfizer and Roche, Regenxbio benefits from FDA boost for DMD gene therapy

Source: 
Fierce Biotech
snippet: 

The FDA has boosted Regenxbio’s attempt to move five adeno-associated virus (AAV) drugs into pivotal trials or onto the market by 2025. The agency has given the company a fast-track designation that could accelerate its bid to muscle in on the Duchenne muscular dystrophy (DMD) sector.